Routine Cerebrospinal Fluid (CSF) Parameters in Patients With Spinal Muscular Atrophy (SMA) Treated With Nusinersen

Background: Nusinersen is an antisense-oligonucleotide (ASO) approved for treatment of 5q-spinal muscular atrophy (SMA). Since the drug cannot cross the blood-brain barrier (BBB), it must be administered into the cerebrospinal fluid (CSF) space repeatedly by lumbar puncture. However, little is known...

Descripción completa

Detalles Bibliográficos
Autores principales: Wurster, Claudia D., Koch, Jan C., Cordts, Isabell, Dreyhaupt, Jens, Otto, Markus, Uzelac, Zeljko, Witzel, Simon, Winter, Benedikt, Kocak, Tugrul, Schocke, Michael, Weydt, Patrick, Wollinsky, Kurt, Ludolph, Albert C., Deschauer, Marcus, Lingor, Paul, Tumani, Hayrettin, Hermann, Andreas, Günther, René
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2019
Materias:
Neurology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6854024/
https://www.ncbi.nlm.nih.gov/pubmed/31787927
http://dx.doi.org/10.3389/fneur.2019.01179

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6854024/
https://www.ncbi.nlm.nih.gov/pubmed/31787927
http://dx.doi.org/10.3389/fneur.2019.01179

Ejemplares similares